Provided by Tiger Trade Technology Pte. Ltd.

iShares Global Healthcare ETF

102.16
-0.1100-0.11%
Post-market: 102.00-0.1600-0.16%19:30 EDT
Volume:1.37M
Turnover:139.66M
Market Cap:4.20B
PE:-99.35
High:102.35
Open:102.06
Low:101.31
Close:102.27
52wk High:107.69
52wk Low:85.36
Shares:41.10M
Float Shares:41.10M
Volume Ratio:10.89
T/O Rate:3.32%
Dividend:1.44
Dividend Rate:1.41%
EPS(TTM):-1.0283
EPS(LYR):-1.0283
ROE:-8.66%
ROA:0.90%
PB:1.08
PE(LYR):-99.35

Loading ...

Eli Lilly Stock (LLY) Has 45% Upside, Says Citigroup

TIPRANKS
·
Yesterday

Novo Nordisk is Dropping Some Weight. it Still Faces a Bigger Challenge.

Dow Jones
·
Yesterday

Eli Lilly Exec Says Co NOW Has More than 30% Share in New Starts Within Oral Obesity Treatment Market -Morgan Stanley Conf

THOMSON REUTERS
·
Yesterday

Eli Lilly and Co Stock (LLY) Moved Up by 3.01% on Sep 14: Drivers Behind the Movement

TradingKey
·
Yesterday

UnitedHealth Earnings Growth Outlook Unlikely to Change, UBS Says

MT Newswires Live
·
Sep 14

Dow Jones Top Company Headlines at 11 am ET: Microsoft Sets Limits for AI Models as Altman Details Control Risks | Dell's ...

Dow Jones
·
Sep 14

Eli Lilly Announces R$ 0.2 Per Unit Dividend for 3Q 2026 BDRs

Reuters
·
Sep 14

HealthStream defines ECWP enterprise category

TIPRANKS
·
Sep 14

Sector Update: Healthcare Stocks Rise Premarket Monday

MT Newswires Live
·
Sep 14

Evercore ISI Remains a Buy on UnitedHealth (UNH)

TIPRANKS
·
Sep 14

U.S. Stocks on the MOVE-US Energy Stocks, Baldwin, Johnson & Johnson

Reuters
·
Sep 14

J&J - Jnj Reports Rybrevant Plus Chemotherapy Extends Pfs2 by 10.8 Months in Nsclc

THOMSON REUTERS
·
Sep 14

Johnson & Johnson’s Rybrevant® (Amivantamab-Vmjw) Plus Chemotherapy Delivers Longest Reported Median Overall Survival in Egfr Exon 20 Insertion Mutation-Positive Lung Cancer

THOMSON REUTERS
·
Sep 14

J&J - Jnj Reports no New Safety Signals for Rybrevant Plus Chemotherapy in Nsclc Study

THOMSON REUTERS
·
Sep 14

OptimizeRx Expands Natural Language Audience Builder to Unify HCP and DTC Audience Intelligence

GlobeNewswire
·
Sep 14

Potential Buyer Emerges for Johnson & Johnson's Orthopedics Unit

Deep News
·
Sep 14

Perspective Therapeutics Enters Cancer Clinical Trial Collaboration With Merck; Shares Up Pre-Bell

MT Newswires Live
·
Sep 14

Healthcare Costs Are Rising Twice as Fast as Everything Else: Inside Milliman’s Healthcare Inflation ETFs (MHIG, MHIP)

TIPRANKS
·
Sep 14

Perspective Therapeutics Partners with Merck to Test [212Pb]PSV359 with Keytruda in FAP-Α-Positive Solid Tumors

Reuters
·
Sep 14

Perspective Therapeutics, - Co Sponsors Study; Merck Provides Pembrolizumab at no Cost

THOMSON REUTERS
·
Sep 14